Glycomacropeptide for Management of Insulin Resistance and Liver Metabolic Perturbations.

ABSTRACT:

Background and aims

The increasing prevalence and absence of effective global treatment for metabolic syndrome (MetS) are alarming given the potential progression to severe non-communicable disorders such as type 2 diabetes and nonalcoholic fatty liver disease. The purpose of this study was to investigate the regulatory role of glycomacropeptide (GMP), a powerful milk peptide, in insulin resistance and liver dysmetabolism, two central MetS conditions.

Materials and methods

C57BL/6 male mice were fed a chow (Ctrl), high-fat, high-sucrose (HFHS) diet or HFHS diet along with GMP (200 mg/kg/day) administered by gavage for 12 weeks.

Results

GMP lowered plasma insulin levels (in response to oral glucose tolerance test) and HOMA-IR index, indicating a more elevated systemic

SUBMITTER: Sauve MF 

PROVIDER: S-EPMC8469639 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature